IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors
Clinical trial NCT05972460 · UNKNOWN
Trial details
- NCT number
- NCT05972460
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-18
- Primary completion
- 2023-12-01
- Enrollment
- 108
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.